(NHC) National HealthCare - Ratings and Ratios
Nursing Homes, Assisted Living, Memory Care, Home Care
NHC EPS (Earnings per Share)
NHC Revenue
Description: NHC National HealthCare
National HealthCare Corporation (NHC) is a healthcare company operating in the United States, specifically in the Health Care Facilities sub-industry. The companys stock is listed on the NYSE MKT exchange under the ticker symbol NHC.
To evaluate NHCs performance, key financial metrics such as Return on Equity (ROE) and Price-to-Earnings (P/E) ratio are crucial. NHCs ROE stands at 11.03%, indicating a relatively stable return for shareholders. The P/E ratio is 13.96, suggesting that the stock may be undervalued compared to its earnings. Additionally, the Market Capitalization of $1.49 billion categorizes NHC as a mid-cap stock, potentially offering a balance between growth and stability.
The healthcare facilities sector is driven by demographic trends, such as an aging population, and regulatory changes. Key economic drivers include occupancy rates, Medicare/Medicaid reimbursement rates, and the overall demand for healthcare services. To assess NHCs operational performance, metrics such as revenue growth, same-facility sales growth, and operating margins are essential. A thorough analysis of these KPIs can help identify areas of strength and potential improvement.
NHCs stock price movements can be analyzed in the context of its volatility, measured by the Average True Range (ATR). A relatively low beta of 0.591 indicates that NHCs stock price is less sensitive to market fluctuations, potentially making it a defensive investment. To further evaluate the stocks potential, an examination of its trading volume, short interest, and institutional ownership can provide valuable insights.
NHC Stock Overview
| Market Cap in USD | 1,888m |
| Sub-Industry | Health Care Facilities |
| IPO / Inception | 1987-01-20 |
NHC Stock Ratings
| Growth Rating | 53.0% |
| Fundamental | 77.2% |
| Dividend Rating | 52.8% |
| Return 12m vs S&P 500 | -12.9% |
| Analyst Rating | - |
NHC Dividends
| Dividend Yield 12m | 2.05% |
| Yield on Cost 5y | 4.57% |
| Annual Growth 5y | 3.86% |
| Payout Consistency | 75.4% |
| Payout Ratio | 37.3% |
NHC Growth Ratios
| Growth Correlation 3m | 94.4% |
| Growth Correlation 12m | -1.3% |
| Growth Correlation 5y | 67.4% |
| CAGR 5y | 31.48% |
| CAGR/Max DD 3y (Calmar Ratio) | 0.94 |
| CAGR/Mean DD 3y (Pain Ratio) | 3.15 |
| Sharpe Ratio 12m | -0.79 |
| Alpha | -8.12 |
| Beta | 0.594 |
| Volatility | 26.08% |
| Current Volume | 68.3k |
| Average Volume 20d | 67.3k |
| Stop Loss | 117.9 (-3.3%) |
| Signal | 0.07 |
Piotroski VR‑10 (Strict, 0-10) 8.5
| Net Income (104.8m TTM) > 0 and > 6% of Revenue (6% = 87.4m TTM) |
| FCFTA 0.08 (>2.0%) and ΔFCFTA 1.67pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 13.35% (prev 19.61%; Δ -6.25pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.10 (>3.0%) and CFO 149.1m > Net Income 104.8m (YES >=105%, WARN >=100%) |
| Net Debt (61.6m) to EBITDA (186.3m) ratio: 0.33 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.72 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (15.6m) change vs 12m ago 0.28% (target <= -2.0% for YES) |
| Gross Margin 38.04% (prev 37.81%; Δ 0.23pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 100.4% (prev 87.91%; Δ 12.46pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 17.37 (EBITDA TTM 186.3m / Interest Expense TTM 8.19m) >= 6 (WARN >= 3) |
Altman Z'' 4.66
| (A) 0.12 = (Total Current Assets 463.2m - Total Current Liabilities 268.7m) / Total Assets 1.56b |
| (B) 0.50 = Retained Earnings (Balance) 788.8m / Total Assets 1.56b |
| (C) 0.10 = EBIT TTM 142.2m / Avg Total Assets 1.45b |
| (D) 1.47 = Book Value of Equity 787.0m / Total Liabilities 536.8m |
| Total Rating: 4.66 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 77.16
| 1. Piotroski 8.50pt = 3.50 |
| 2. FCF Yield 6.60% = 3.30 |
| 3. FCF Margin 8.17% = 2.04 |
| 4. Debt/Equity 0.17 = 2.49 |
| 5. Debt/Ebitda 0.33 = 2.42 |
| 6. ROIC - WACC (= 1.85)% = 2.32 |
| 7. RoE 10.50% = 0.88 |
| 8. Rev. Trend 93.57% = 7.02 |
| 9. EPS Trend 64.19% = 3.21 |
What is the price of NHC shares?
Over the past week, the price has changed by +3.85%, over one month by +6.32%, over three months by +24.18% and over the past year by +0.60%.
Is National HealthCare a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of NHC is around 131.28 USD . This means that NHC is currently overvalued and has a potential downside of 7.65%.
Is NHC a buy, sell or hold?
What are the forecasts/targets for the NHC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 6.2 | -95% |
| Analysts Target Price | 6.2 | -95% |
| ValueRay Target Price | 145.2 | 19% |
Last update: 2025-10-04 03:57
NHC Fundamental Data Overview
P/E Trailing = 18.1791
P/S = 1.2948
P/B = 1.8475
Beta = 0.594
Revenue TTM = 1.46b USD
EBIT TTM = 142.2m USD
EBITDA TTM = 186.3m USD
Long Term Debt = 102.5m USD (from longTermDebt, last quarter)
Short Term Debt = 40.2m USD (from shortTermDebt, last quarter)
Debt = 172.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 61.6m USD (from netDebt column, last quarter)
Enterprise Value = 1.80b USD (1.89b + Debt 172.6m - CCE 257.6m)
Interest Coverage Ratio = 17.37 (Ebit TTM 142.2m / Interest Expense TTM 8.19m)
FCF Yield = 6.60% (FCF TTM 118.9m / Enterprise Value 1.80b)
FCF Margin = 8.17% (FCF TTM 118.9m / Revenue TTM 1.46b)
Net Margin = 7.20% (Net Income TTM 104.8m / Revenue TTM 1.46b)
Gross Margin = 38.04% ((Revenue TTM 1.46b - Cost of Revenue TTM 902.4m) / Revenue TTM)
Gross Margin QoQ = 39.28% (prev 38.95%)
Tobins Q-Ratio = 1.15 (Enterprise Value 1.80b / Total Assets 1.56b)
Interest Expense / Debt = 1.15% (Interest Expense 1.99m / Debt 172.6m)
Taxrate = 25.04% (8.05m / 32.2m)
NOPAT = 106.6m (EBIT 142.2m * (1 - 25.04%))
Current Ratio = 1.72 (Total Current Assets 463.2m / Total Current Liabilities 268.7m)
Debt / Equity = 0.17 (Debt 172.6m / totalStockholderEquity, last quarter 1.02b)
Debt / EBITDA = 0.33 (Net Debt 61.6m / EBITDA 186.3m)
Debt / FCF = 0.52 (Net Debt 61.6m / FCF TTM 118.9m)
Total Stockholder Equity = 997.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 6.71% (Net Income 104.8m / Total Assets 1.56b)
RoE = 10.50% (Net Income TTM 104.8m / Total Stockholder Equity 997.6m)
RoCE = 12.93% (EBIT 142.2m / Capital Employed (Equity 997.6m + L.T.Debt 102.5m))
RoIC = 9.44% (NOPAT 106.6m / Invested Capital 1.13b)
WACC = 7.59% (E(1.89b)/V(2.06b) * Re(8.20%) + D(172.6m)/V(2.06b) * Rd(1.15%) * (1-Tc(0.25)))
Discount Rate = 8.20% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.36%
[DCF Debug] Terminal Value 69.77% ; FCFE base≈103.2m ; Y1≈67.7m ; Y5≈31.0m
Fair Price DCF = 38.26 (DCF Value 593.0m / Shares Outstanding 15.5m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 64.19 | EPS CAGR: 161.1% | SUE: N/A | # QB: 0
Revenue Correlation: 93.57 | Revenue CAGR: 12.35% | SUE: N/A | # QB: 0
Additional Sources for NHC Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle